Next generation mitral valve, designed to facilitate patient lifetime management reports first uses in sternotomy, Minimally Invasive Cardiac Surgery (MICS) and robotic cases.
SUNRISE-II feasibility trial marks the company’s entry into U.S. clinical development, advancing minimally invasive, anesthesia-free treatment approach
Edwards announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue.
The deal would fold the FDA-cleared Hotwire system, and the team behind Farapulse, into J&J’s expanding cardiac ablation business.
The TAVVE study will begin later this year with ten patients, whose 30-day safety results will be submitted to the FDA.
Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe.
CathWorks FFRangio System employs drug-free, wire-free technology for comprehensive physiological assessment.
Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, this next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease, according to the company.
Hologic announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately upon closing of the previously announced company acquisition.